WO2008131047A3 - Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism - Google Patents

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism Download PDF

Info

Publication number
WO2008131047A3
WO2008131047A3 PCT/US2008/060542 US2008060542W WO2008131047A3 WO 2008131047 A3 WO2008131047 A3 WO 2008131047A3 US 2008060542 W US2008060542 W US 2008060542W WO 2008131047 A3 WO2008131047 A3 WO 2008131047A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasminogen activator
lipid metabolism
inhibitors
methods
activator inhibitor
Prior art date
Application number
PCT/US2008/060542
Other languages
French (fr)
Other versions
WO2008131047A2 (en
Inventor
Daniel A Lawrence
Dudley K Strickland
Jacqueline Cale
Enming Joe Su
Cory Emal
Mark Warnock
Original Assignee
Univ Michigan
Daniel A Lawrence
Dudley K Strickland
Jacqueline Cale
Enming Joe Su
Cory Emal
Mark Warnock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Daniel A Lawrence, Dudley K Strickland, Jacqueline Cale, Enming Joe Su, Cory Emal, Mark Warnock filed Critical Univ Michigan
Publication of WO2008131047A2 publication Critical patent/WO2008131047A2/en
Publication of WO2008131047A3 publication Critical patent/WO2008131047A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/88—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to plasminogen activator- 1 (PAl-1I) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
PCT/US2008/060542 2007-04-16 2008-04-16 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism WO2008131047A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91207107P 2007-04-16 2007-04-16
US60/912,071 2007-04-16

Publications (2)

Publication Number Publication Date
WO2008131047A2 WO2008131047A2 (en) 2008-10-30
WO2008131047A3 true WO2008131047A3 (en) 2009-01-08

Family

ID=39580203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/060542 WO2008131047A2 (en) 2007-04-16 2008-04-16 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism

Country Status (2)

Country Link
US (2) US8759327B2 (en)
WO (1) WO2008131047A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120744B2 (en) 2007-04-16 2015-09-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
GB0819958D0 (en) * 2008-10-31 2008-12-10 Provexis Natural Products Ltd Therapeutic compositions
GB0819959D0 (en) 2008-10-31 2008-12-10 Provexis Natural Products Ltd Fruit extracts
JP6031355B2 (en) 2009-10-11 2016-11-24 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー Biocompatible polymers for medical devices
DE102011088982A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Detergents and cleaning agents with improved performance
DE102011088984A1 (en) 2011-12-19 2013-06-20 Henkel Ag & Co. Kgaa Detergents and cleaning agents with improved performance
US20130164228A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Compositions comprising gallates and gallamides
EP3312155B1 (en) 2012-02-03 2020-08-05 Rutgers, The State University of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
US11472918B2 (en) 2012-02-03 2022-10-18 Rutgers, The State University Of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
AU2013252637B2 (en) 2012-04-23 2016-12-22 Provexis Natural Products Limited Use of tomato extract as antihypertensive agent and process for making water soluble sugar free tomato extract
CN105008323B (en) 2012-10-31 2018-11-06 密歇根大学董事会 - 1 inhibitor of Plasminogen activator and its application method
GB201223365D0 (en) 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
AR102361A1 (en) * 2014-10-29 2017-02-22 Lilly Co Eli METHYL-QUINOLINE COMPOUNDS USEFUL TO INHIBIT THE MICROSOMAL PROSTAGLANDIN E2 SYNTHESA-1
US10774030B2 (en) 2014-12-23 2020-09-15 Rutgers, The State University Of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
KR20230048169A (en) 2016-11-02 2023-04-10 프로벡시스 내추럴 프로덕츠 리미티드 Water soluble tomato extract protects against adverse effects of air pollution
AU2018307807B2 (en) 2017-07-27 2024-05-02 Eastern Michigan University Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
US10927138B2 (en) * 2018-05-29 2021-02-23 Syneurx International (Taiwan) Corp. Inhibitors of D-amino acid oxidase (DAAO) and uses thereof
US20200163850A1 (en) * 2018-11-24 2020-05-28 Momentive Performance Materials Gmbh Use of polyhydroxyaromatic compounds for the treatment of fibrous amino acid based substrates
CN110448563A (en) * 2019-07-19 2019-11-15 南京中医药大学 Application of 1,2,3,4, the 6- Penta-O-galloyl-D-glucopyranose in preparation prevention and treatment osteoporosis drug
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
KR20230004765A (en) 2020-04-23 2023-01-06 신유알엑스 인터내셔널 (타이완) 코포레이션 COMPOUNDS AND PHARMACEUTICAL USES THEREOF
US20230305023A1 (en) 2020-06-25 2023-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
CN113679039B (en) * 2021-05-12 2023-05-09 浙江大学 Polyethylene glycol gallate protein carrier synergist and preparation method and application thereof
CN115368278B (en) * 2022-10-25 2023-04-11 北京鑫开元医药科技有限公司 Method for preparing benzenesulfonic acid compound by hydrolyzing benzenesulfonamide compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479198B2 (en) * 2000-02-01 2002-11-12 Fuji Photo Film Co., Ltd. Silver halide light-sensitive material containing tanning developing agent
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003055843A1 (en) 2001-12-27 2003-07-10 Bayer Healthcare Ag Agaricoglycerides and analogs
US20060058243A1 (en) * 2002-07-24 2006-03-16 Xiaozhuo Chen Methods and compositions for treating diabetes mellitis
CA2527052A1 (en) 2003-05-28 2005-01-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Angiogenic agents from plant extracts, gallic acid, and derivatives
US20090069302A1 (en) * 2006-01-20 2009-03-12 Smithkline Beecham Corporation Chemical compounds

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BONCORAGLIO G B ET AL: "An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke", CEREBROVASCULAR DISEASES 200607 CH, vol. 22, no. 2-3, July 2006 (2006-07-01), pages 191 - 195, XP008094227, ISSN: 1015-9770 *
CHEN CHIH-HUNG ET AL: "4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke.", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 142, no. 2, August 2003 (2003-08-01), pages 100 - 105, XP002489577, ISSN: 0022-2143 *
DICHTL WOLFGANG ET AL: "In vivo stimulation by vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element", THROMBOSIS AND HAEMOSTASIS, vol. 84, no. 4, October 2000 (2000-10-01), pages 706 - 711, XP008094149, ISSN: 0340-6245 *
GORLATOVA NATALIA V ET AL: "Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 23 MAR 2007, vol. 282, no. 12, 23 March 2007 (2007-03-23), pages 9288 - 9296, XP002489583, ISSN: 0021-9258 *
JENSEN JAN K ET AL: "Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library", BIOCHEM. J.; BIOCHEMICAL JOURNAL NOV 1 2006, vol. 399, no. 3, 1 November 2006 (2006-11-01), pages 387 - 396, XP002489581 *
LOPES C ET AL: "PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population.", DIABETOLOGIA SEP 2003, vol. 46, no. 9, September 2003 (2003-09-01), pages 1284 - 1290, XP002489579, ISSN: 0012-186X *
NILSSON LENNART ET AL: "VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: Involvement of the VLDL receptor", JOURNAL OF LIPID RESEARCH, vol. 40, no. 5, May 1999 (1999-05-01), pages 913 - 919, XP002489580, ISSN: 0022-2275 *
RODENBURG K W ET AL: "Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.", THE BIOCHEMICAL JOURNAL 1 JAN 1998, vol. 329 ( Pt 1), 1 January 1998 (1998-01-01), pages 55 - 63, XP002489582, ISSN: 0264-6021 *
SCHÄFER K ET AL: "Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY AUG 2001, vol. 15, no. 10, August 2001 (2001-08-01), pages 1840 - 1842, XP002489578, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
US8759327B2 (en) 2014-06-24
US20140343321A1 (en) 2014-11-20
US9096501B2 (en) 2015-08-04
WO2008131047A2 (en) 2008-10-30
US20090011055A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2008131047A3 (en) Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2010074588A8 (en) Pharmaceutical compounds
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
IL184678A0 (en) Proteasome inhibitors and methods of using the same
MX2009006536A (en) Organic compounds and their uses.
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2009027346A3 (en) 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
TNSN08400A1 (en) Organic compounds and their uses
JO3358B1 (en) Ocular Allergy Treatments
WO2008043087A3 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2006057997A3 (en) Plasmin-inhibitory therapies
WO2007121125A3 (en) Hcv inhibitors
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
NO20093542L (en) Inhibition of tumor metastasis by anti-neuropilin 2 antibodies
MX2009002960A (en) Serine hydrolase inhibitors.
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
TNSN08496A1 (en) Aminothiazoles and their uses
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
WO2009023160A8 (en) Novel inhibitors of bacterial sortase enzymes and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08746036

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08746036

Country of ref document: EP

Kind code of ref document: A2